Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Cited by (1,001)

Items 101–200 of 1,001

1. Engineering Gene Therapy: Advances and Barriers
   Alireza Shahryari, Ingo Burtscher, Zahra Nazari, Heiko Lickert · 2021 · Advanced Therapeutics
2. Residual cardiovascular risk: When should we treat it?
   Francisco Gómez-Delgado, Manuel Raya‐Cruz, Niki Katsiki, Javier Delgado‐Lista, Pablo Pérez‐Martínez · 2023 · European Journal of Internal Medicine
3. High lipoprotein(a): Actionable strategies for risk assessment and mitigation
   Gissette Reyes‐Soffer, Calvin Yeang, Erin D. Michos, Wess Boatwright, Christie Mitchell Ballantyne · 2024 · American Journal of Preventive Cardiology
4. New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?
   Dan Atar, J. Wouter Jukema, Bart Molemans, Pam R. Taub, Shinya Goto, François Mach, Cesar Cerezo Olmos, James A. Underberg, ANTHONY C. KEECH, Lale S Tokgözoğlu et al. · 2021 · Atherosclerosis
5. Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein
   Peter E Thomas, Signe Vedel‐Krogh, Pia R. Kamstrup, Børge Grønne Nordestgaard · 2023 · European Heart Journal
6. Multiancestry Genome-Wide Association Study of Aortic Stenosis Identifies Multiple Novel Loci in the Million Veteran Program
   Small, Aeron M., Peloso, Gina M., Linefsky, Jason, Aragam, Jayashri, Galloway, Ashley, Tanukonda, Vidisha, Wang, Lu-Chen, Yu, Zhi, Sunitha Selvaraj, Margaret, Farber-Eger, Eric H. et al. · 2023 · Circulation
7. The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering
   Michelle L. O’Donoghue, Robert S. Rosenson, J. Antonio G. López, Norman E. Lepor, Seth J. Baum, Elmer Stout, Daniel Gaudet, Beat Knüsel, Julia Kuder, Sabina A. Murphy et al. · 2024 · Journal of the American College of Cardiology
8. Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study
   Langsted, Anne, Nordestgaard, Børge G, Kamstrup, Pia R · 2021 · European Heart Journal
9. Development of an LC-MRM-MS-Based Candidate Reference Measurement Procedure for Standardization of Serum Apolipoprotein (a) Tests
   L. Renee Ruhaak, Fred P.H.T.M. Romijn, Ilijana Begcevic Brkovic, Zsuzsanna Kuklenyik, Julia Dittrich, Uta Ceglarek, Andrew N. Hoofnagle, Harald Althaus, Eduardo Anglés‐Cano, Stefan Coassin et al. · 2023 · Clinical Chemistry
10. Lipoprotein(a), platelet function and cardiovascular disease
    Harpreet Singh Bhatia, Richard Clinton Becker, Gregor Leibundgut, Mitul P. Patel, Paul A Lacaze, Andrew Maxwell Tonkin, Jagat Narula, Sotirios Tsimikas · 2023 · Nature Reviews Cardiology
11. Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis
    Patrick M. Moriarty, Lauryn K. Gorby, Erik S.G. Stroes, John J.P. Kastelein, Michael H. Davidson, Sotirios Tsimikas · 2020 · Current Atherosclerosis Reports
12. Diacylglycerols and Lysophosphatidic Acid, Enriched on Lipoprotein(a), Contribute to Monocyte Inflammation
    Kim E. Dzobo, Arjen J. Cupido, Barend M. Mol, Lotte C.A. Stiekema, Miranda Versloot, Maaike Winkelmeijer, Jorge Peter, Anne-Marije Pennekamp, Stefan R. Havik, Frédéric Maxime Vaz et al. · 2024 · Arteriosclerosis Thrombosis and Vascular Biology
13. Association of <i>FADS1/2</i> Locus Variants and Polyunsaturated Fatty Acids With Aortic Stenosis
    Chen, Hao Yu, Cairns, Benjamin J., Small, Aeron M., Burr, Hannah A., Ambikkumar, Athithan, Martinsson, Andreas, Thériault, Sébastien, Munter, Hans Markus, Steffen, Brian, Zhang, Richard et al. · 2020 · JAMA Cardiology
14. Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
    Michael J. Wilkinson, Norman E. Lepor, Erin D. Michos · 2023 · Journal of the American Heart Association
15. Advances in biological therapies for dyslipidemias and atherosclerosis
    Eftaxia-Konstantina Valanti, Katerina Dalakoura-Karagkouni, Gerasimos Siasos, Dimitris Kardassis, Aristides G. Eliopoulos, Despina Sanoudou · 2020 · Metabolism
16. Lipid Lowering Drugs: Present Status and Future Developments
    Ruscica, Massimiliano, Ferri, Nicola, Santos, Raul D., Sirtori, Cesare R., Corsini, Alberto · 2021 · Current Atherosclerosis Reports
17. Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies
    Harpreet Singh Bhatia, Michael J. Wilkinson · 2022 · Journal of Clinical Medicine
18. Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees
    Florian Kronenberg, Samia Mora, Erik S.G. Stroes · 2022 · Current Opinion in Lipidology
19. Novel emerging therapies in atherosclerosis targeting lipid metabolism
    Manasvi Gupta, Colin Blumenthal, Subhankar Chatterjee, Dhrubajyoti Bandyopadhyay, Vardhmaan Jain, Carl J. Lavie, Salim S. Virani, Kausik Kumar Ray, Wilbert S. Aronow, Raktim K. Ghosh · 2020 · Expert Opinion on Investigational Drugs
20. Lipoprotein(a) is robustly associated with aortic valve calcium
    Yannick Kaiser, Sunny S Singh, Kang H. Zheng, Rutger Verbeek, Maryam Kavousi, Sara‐Joan Pinto‐Sietsma, Meike Willemijn Vernooij, Eric J.G. Sijbrands, S. Matthijs Boekholdt, Yolanda B. de Rijke et al. · 2021 · Heart
21. Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis
    Ioannis T. Farmakis, Ioannis Doundoulakis, Areti Pagiantza, Stefanos Zafeiropoulos, Christina Antza, Haralambos I. Karvounis, George A. Giannakoulas · 2020 · Journal of Cardiovascular Pharmacology
22. Molecular Biomarkers for Cardiometabolic Disease: Risk Assessment in Young Individuals
    Usman A. Tahir, Robert Edgardo Gerszten · 2023 · Circulation Research
23. Genetics and Pathophysiological Mechanisms of Lipoprotein(a)‐Associated Cardiovascular Risk
    Annabelle Santos Volgman, Marlys L. Koschinsky, Anurag Mehta, Robert S. Rosenson · 2024 · Journal of the American Heart Association
24. Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy
    Bożena Sosnowska, Stanisław Surma, Maciej Banach · 2022 · Pharmaceuticals
25. Lipid lowering therapy in cardiovascular disease: From myth to molecular reality
    Philipp Mourikis, Saif Zako, Lisa Dannenberg, Amir M. Nia, Yvonne Heinen, Lucas Busch, Hannah Richter, Thomas Hohlfeld, Tobias Zeus, Malte Kelm et al. · 2020 · Pharmacology & Therapeutics
26. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target
    Stefania Angela Di Fusco, Marcello Arca, Pietro Scicchitano, Alessandro Alonzo, Francesco Perone, Michele Massimo Gulizia, Domenico Gabrielli, Fabrizio Giovanni Oliva, Giuseppe Imperoli, Furio Colivicchi · 2022 · Heart
27. Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes
    Simon C Kraler, Florian A. Wenzl, Georgios A. Georgiopoulos, Slayman Nabih Obeid, Luca Liberale, Arnold von Eckardstein, Olivier Müller, François Mach, Lorenz Räber, Sylvain Losdat et al. · 2022 · European Heart Journal
28. LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics
    Erfan Tasdighi, Rishav Adhikari, Omar Almaadawy, Thorsten Martin Leucker, Michael Joseph Blaha · 2023 · The Annual Review of Pharmacology and Toxicology
29. Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease
    David A. Rider, Mona Eisermann, Kathrin Löffler, Manuela Aleku, Daniel I. Swerdlow, Sibylle Dames, Judith Hauptmann, Eliot Morrison, Marie Lindholm, Steffen Schubert et al. · 2022 · Atherosclerosis
30. Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
    Clarice Gareri, Alberto Polimeni, Salvatore A. Giordano, Laura Tammè, Antonio Curcio, Ciro Indolfi · 2022 · Journal of Clinical Medicine
31. Trends and consequences of lipoprotein(a) testing: Cross-sectional and longitudinal health insurance claims database analyses
    Paulina Elena Stürzebecher, Jessica Schorr, Sven H. G. Klebs, Ulrich Laufs · 2023 · Atherosclerosis
32. Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease
    Wayne C. Zheng, William Chan, Anthony Michael Dart, James A. Shaw · 2023 · European Heart Journal - Cardiovascular Pharmacotherapy
33. Lipoprotein(a) and Cardiovascular Diseases
    Hannah Miksenas, James L. Januzzi, Pradeep Natarajan · 2021 · JAMA
34. Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events
    Marcello Ricardo Paulista Markus, Till Ittermann, Joany Mariño, Sabine Schipf, Martin Bahls, Stephanie Könemann, Bishwas Chamling, Henry Völzke, Nágila Raquel Teixeira Damasceno, Raul Dias Santos et al. · 2025 · European Heart Journal
35. The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia
    Jing Pang, Dick C. Chan, Gerald Francis Watts · 2020 · Current Atherosclerosis Reports
36. Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics
    Daniel I. Swerdlow, David A. Rider, Arash Yavari, Marie Lindholm, G. Campion, Steven E. Nissen · 2021 · Cardiovascular Research
37. Hepatocyte targeting <i>via</i> the asialoglycoprotein receptor
    Ramírez-Cortés, Fabricio, Ménová, Petra · 2025 · RSC Medicinal Chemistry
38. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
    Barbara Cybulska, Longina Kłosiewicz−Latoszek, Peter Edward Penson, Maciej Banach · 2020 · Progress in Cardiovascular Diseases
39. Finding very high lipoprotein(a): the need for routine assessment
    Nick S. Nurmohamed, Yannick Kaiser, Pauline C E Schuitema, Shirin Ibrahim, Melchior C. Nierman, Johan Fischer, Steven A. J. Chamuleau, Paul Knaapen, Erik S.G. Stroes · 2021 · European Journal of Preventive Cardiology
40. Lipoprotein (a), Inflammation, and Atherosclerosis
    Stefania Angela Di Fusco, Aldo Pietro Maggioni, Pietro Scicchitano, Marco Zuin, Emilia D’Elia, Furio Colivicchi · 2023 · Journal of Clinical Medicine
41. Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations
    Nishant P. Shah, Neha J. Pajidipati, Robert W. McGarrah, Ann Marie Návar, Sreekanth Vemulapalli, Michael A. Blazing, Svati Hasmukh Shah, Adrian F. Hernandez, Manesh R. Patel · 2020 · The American Journal of Cardiology
42. Therapeutic RNA-silencing oligonucleotides in metabolic diseases
    Goga, Algera, Stoffel, Markus · 2022 · Nature Reviews Drug Discovery
43. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    Teresa Coelho, Yukio Ando, Merrill Douglas Benson, John L. Berk, Márcia Waddington‐Cruz, P. James B. Dyck, Julian David Gillmore, Sami L. Khella, William J. Litchy, Laura Piera Obici et al. · 2021 · Neurology and Therapy
44. Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
    Panagiotis Theofilis, Aikaterini Vordoni, Maria Koukoulaki, Georgios Vlachopanos, Rigas Kalaitzidis · 2021 · American Journal of Nephrology
45. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes
    Parsa Akbari, Olukayode Ayodeji Sosina, Jonas Bovijn, Karl Landheer, Jonas Bille Nielsen, Minhee Kim, Senem Aykul, Tanima De, Mary E. Haas, George Hindy et al. · 2022 · Nature Communications
46. Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis
    Panteleimon Pantelidis, Evangelos K. Oikonomou, Stamatios Lampsas, George Ε. Zakynthinos, Antonios Lysandrou, Konstantinos I. Kalogeras, Efstratios Katsianos, Panagiotis Theofilis, Gerasimos Siasos, Michael Vavuranakis et al. · 2023 · Cardiovascular Research
47. New Trends in Dyslipidemia Treatment
    Albert Youngwoo Jang, Soo Lim, Sang-Ho Jo, Seung Hwan Han, Kwang Kon Koh · 2020 · Circulation Journal
48. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies
    Ibrahim S. Alhomoud, Azita H. Talasaz, Anurag Mehta, Michael S. Kelly, Evan M. Sisson, John D. Bucheit, Roy Brown, Dave L. Dixon · 2023 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
49. Lipoprotein(a)
    Florian Kronenberg · 2021 · Handbook of experimental pharmacology
50. Lipoprotein(a): from Causality to Treatment
    Florian Kronenberg · 2024 · Current Atherosclerosis Reports
51. Organ cross-talk: molecular mechanisms, biological functions, and therapeutic interventions for diseases
    Huiting Che, Yidan Gao, Yonghu Xu, Hui Xu, Roland Eils, Mei Tian · 2026 · Signal Transduction and Targeted Therapy
52. The Interplay Between Immunity, Inflammation and Endothelial Dysfunction
    Ying Jie Chee, Rinkoo Dalan, Christine Cheung · 2025 · International Journal of Molecular Sciences
53. Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia
    Leopoldo Pérez de Isla, Gerald Francis Watts, Rodrigo Alonso K, José Luis Díaz-Díaz, Ovidio Muñiz-Grijalvo, Daniel Zambón, Francisco J. Fuentes, Raimundo de Andrés, Teresa Padró, José López‐Miranda et al. · 2020 · European Heart Journal
54. Nonviral delivery systems for antisense oligonucleotide therapeutics
    Si Qin Huang, Xinyan Hao, Yongjiang Li, Junyong Wu, Daxiong Xiang, Shilin Luo · 2022 · Biomaterials Research
55. Lipoprotein(a) and inflammation- pathophysiological links and clinical implications for cardiovascular disease
    Spyridon Simantiris, Alexios S. Antonopoulos, Charalampos Papastamos, Georgios Benetos, Νικόλαος Κούμαλλος, Konstantinos P Tsioufis, Dimitris Tousoulis · 2022 · Journal of clinical lipidology
56. Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database
    Diane Elaine MacDougall, Anne Tybjærg‐Hansen, Joshua W. Knowles, Theresa Stern, Bonnie Hartsuff, Mary P. McGowan, Seth J. Baum, Katherine A. Wilemon, Børge Grønne Nordestgaard · 2025 · European Heart Journal
57. Existing and emerging therapies for the treatment of familial hypercholesterolemia
    Robert S. Rosenson · 2021 · Journal of Lipid Research
58. An RNA/DNA hybrid origami-based nanoplatform for efficient gene therapy
    Xiaohui Wu, Qing Lin Liu, Fengsong Liu, Tiantian Wu, Yingxu Shang, Jianbing Liu, Baoquan Ding · 2021 · Nanoscale
59. Discovery of potent small-molecule inhibitors of lipoprotein(a) formation
    Nuria Diaz, Carlos Perez, Ana Escribano, Gema Sanz, Julián Priego, Celia Lafuente, Mario Barberis, Luis Pablo Calle, Juan F. Espinosa, Birgit T. Priest et al. · 2024 · Nature
60. Lipoprotein(a) and cardiovascular disease
    Michael B. Boffa, Marlys L. Koschinsky · 2024 · Biochemical Journal
61. Development and validation of an isoform-independent monoclonal antibody–based ELISA for measurement of lipoprotein(a)
    Santica M. Marcovina, Nazanin Navabi, Serena Allen, Ayelet Gonen, Joseph Lee Witztum, Sotirios Tsimikas · 2022 · Journal of Lipid Research
62. Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up
    Efthymios Ziogos, Michael Vavuranakis, Tarek Harb, Palmer Foran, Michael Joseph Blaha, Steven Richard Jones, Shenghan Lai, Gary Gerstenblith, Thorsten Martin Leucker · 2023 · European Heart Journal Open
63. Focus on the Most Common Paucisymptomatic Vasculopathic Population, from Diagnosis to Secondary Prevention of Complications
    Eugenio Martelli, Iolanda Enea, Matilde Zamboni, Massimo Federici, Umberto Marcello Bracale, Giuseppe Sangiorgi, Allegra Rosa Martelli, Teresa Messina, Alberto M. Settembrini · 2023 · Diagnostics
64. Lipoprotein(a): Emerging insights and therapeutics
    Gurleen Kaur, Khaled Abdelrahman, Adam N. Berman, David W. Biery, Arthur Shiyovich, Daniel M. Huck, Michael Seth Garshick, Ron Blankstein, Brittany Weber · 2024 · American Journal of Preventive Cardiology
65. Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk
    Tarek Harb, Efthymios Ziogos, Roger Scott Blumenthal, Gary Gerstenblith, Thorsten Martin Leucker · 2024 · European Heart Journal Open
66. Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers
    Robert S. Rosenson, J. Antonio G. López, Daniel Gaudet, Seth J. Baum, Elmer Stout, Norman E. Lepor, Jeong‐Gun Park, Sabina A. Murphy, Beat Knüsel, Jingying Wang et al. · 2025 · JAMA Cardiology
67. Mendelian Randomization: Principles and its usage in Lp(a) research
    Claudia Lamina · 2022 · Atherosclerosis
68. ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease
    Helkkula, Pyry, Kiiskinen, Tuomo, Havulinna, Aki S., Karjalainen, Juha, Koskinen, Seppo, Salomaa, Veikko, Daly, Mark J., Palotie, Aarno, Surakka, Ida, Ripatti, Samuli et al. · 2021 · PLOS Genetics
69. Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study
    Lotte M. de Boer, Albert Wiegman, Jeffrey Kroon, Sotirios Tsimikas, Calvin Yeang, Merel C Peletier, Alma Revers, John J.P. Kastelein, Aeilko Having Zwinderman, Barbara A. Hutten · 2023 · The Lancet Diabetes & Endocrinology
70. Lipoprotein(a) in the Year 2024: A Look Back and a Look Ahead
    Sotirios Tsimikas · 2024 · Arteriosclerosis Thrombosis and Vascular Biology
71. Antisense oligonucleotide based therapeutics and its applications against bacterial infections
    Nupur Angrish, Garima Khare · 2023 · Medicine in Drug Discovery
72. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels
    Bożena Sosnowska, Janina Stępińska, Przemyslaw P. Mitkowski, Agata Magdalena Bielecka-Dabrowa, Beata Bobrowska, Jan Budzianowski, Paweł Burchardt, Krzysztof Chlebus, Piotr Dobrowolski, Mariusz Gąsior et al. · 2024 · Archives of Medical Science
73. N-Acetyl Galactosamine Targeting: Paving the Way for Clinical Application of Nucleotide Medicines in Cardiovascular Diseases
    Erik A.L. Biessen, Theo J.C. van Berkel · 2021 · Arteriosclerosis Thrombosis and Vascular Biology
74. Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study
    Nick S. Nurmohamed, Didier Collard, Laurens F. Reeskamp, Yannick Kaiser, Jeffrey Kroon, Tycho R. Tromp, Bert‐Jan H. van den Born, Michiel Coppens, Alexander P. J. Vlaar, Martijn Beudel et al. · 2021 · Atherosclerosis
75. Per-Particle Cardiovascular Risk of Lipoprotein(a) vs Non-Lp(a) Apolipoprotein B-Containing Lipoproteins
    Nicholas Marston, Giorgio E. M. Melloni, Sabina A. Murphy, Jakub Morze, Frederick Kamanu, Patrick T. Ellinor, Christian Thomas Ruff, Marc Steven Sabatine · 2024 · Journal of the American College of Cardiology
76. Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort
    Eric J. Brandt, Arya Mani, Erica Sarah Spatz, Nihar R. Desai, Khurram Nasir · 2020 · Journal of clinical lipidology
77. β-Cell Dysfunction, Hepatic Lipid Metabolism, and Cardiovascular Health in Type 2 Diabetes: New Directions of Research and Novel Therapeutic Strategies
    Ahmad H. Al-Mrabeh · 2021 · Biomedicines
78. Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know
    Salim S. Virani, Marlys L. Koschinsky, Lisa V. Maher, Anurag Mehta, Carl E. Orringer, Raul Dias Santos, Michael David Shapiro, Joseph J. Saseen · 2022 · Progress in Cardiovascular Diseases
79. Lp(a): a New Pathway to Target?
    Nick S. Nurmohamed, Jordan M Kraaijenhof, Erik S.G. Stroes · 2022 · Current Atherosclerosis Reports
80. Associations of Genetically Predicted Lp(a) (Lipoprotein [a]) Levels With Cardiovascular Traits in Individuals of European and African Ancestry
    Satterfield, Benjamin A., Dikilitas, Ozan, Safarova, Maya S., Clarke, Shoa L., Tcheandjieu, Catherine, Zhu, Xiang, Bastarache, Lisa, Larson, Eric B., Justice, Anne E., Shang, Ning et al. · 2021 · Circulation: Genomic and Precision Medicine
81. Lipoprotein (a) and aortic valve calcium in South Asians compared to other race/ethnic groups
    Minhal Makshood, Parag H. Joshi, Alka M. Kanaya, Colby R. Ayers, Matthew Jay Budoff, Michael Y. Tsai, Michael Joseph Blaha, Erin D. Michos, Wendy S. Post · 2020 · Atherosclerosis
82. The Trajectory of Lipoprotein(a) During the Peri- and Early Postinfarction Period and the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition
    Michael Vavuranakis, Steven Richard Jones, Efthymios Ziogos, Michael Joseph Blaha, Marlene S. Williams, Palmer Foran, Thomas Hellmut Schindler, Shenghan Lai, Steven P. Schulman, Gary Gerstenblith et al. · 2022 · The American Journal of Cardiology
83. Investigation of a nonsense mutation located in the complex KIV-2 copy number variation region of apolipoprotein(a) in 10,910 individuals
    Silvia Di Maio, Rebecca Grüneis, Gertraud Streiter, Claudia Lamina, Manuel Maglione, Sebastian Schönherr, Dietmar Öfner, Barbara Thorand, Annette Peters, Kai‐Uwe Eckardt et al. · 2020 · Genome Medicine
84. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
    Gregory G. Schwartz, Michael J. Szarek, Vera Bittner, Deepak L. Bhatt, Rafael Díaz, Shaun G. Goodman, J. Wouter Jukema, Megan Loy, Garen Z. Manvelian, Robert C. Pordy et al. · 2021 · Diabetes Care
85. Targeting epigenetic modifiers to reprogramme macrophages in non-resolving inflammation-driven atherosclerosis
    Fengyan Jin, Jian Li, Jianfeng Guo, Thorsten Roland Doeppner, Dirk Matthias Hermann, Gang Yao, Yun Dai · 2021 · European Heart Journal Open
86. Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects
    Ewa Karwatowska‐Prokopczuk, Anastasia Lesogor, Jing‐He Yan, Eunju Hurh, Angelika Hoenlinger, Alison Margolskee, Shuting Xia, Sotirios Tsimikas · 2022 · Journal of clinical lipidology
87. Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank
    Paul I. Welsh, Anas Al Zabiby, Hannah Byrne, Harriet R. Benbow, Taha Itani, Gabriella Farries, Madlaina Costa‐Scharplatz, Philippe C. Ferber, Lorraine Martin, Rosemary Brown et al. · 2023 · Atherosclerosis
88. Oxidized Phospholipids and Calcific Aortic Valvular Disease
    Harpreet Singh Bhatia, Marc Richard Dweck, Neil J. Craig, Romain Capoulade, Philippe Pîbarot, Patrick James Trainor, Seamus Paul Whelton, Rishi Raj Rikhi, Kárita Cláudia Freitas Lidani, Wendy S. Post et al. · 2024 · Journal of the American College of Cardiology
89. Non-stenotic Carotid Plaques in Embolic Stroke of Unknown Source
    Joseph Kamtchum Tatuene, Ali Zohair Nomani, Sarina R. Falcione, Danielle Munsterman, Gina P. Sykes, Twinkle Joy, Elena Spronk, María Isabel Vargas, Glen C. Jickling · 2021 · Frontiers in Neurology
90. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients
    Stephen James Nicholls, Adam J. Nelson, Kausik Kumar Ray, Christie Mitchell Ballantyne, Marc Ditmarsch, Douglas F. Kling, Andrew Hsieh, Michael J. Szarek, John J.P. Kastelein, Michael H. Davidson · 2025 · Journal of the American College of Cardiology
91. LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study
    Alexandria M. Doerfler, So Hyun Park, Julia M. Assini, Amer Youssef, Lavanya Saxena, Adam B. Yaseen, Marco De Giorgi, Marcel A. Chuecos, Ayrea E. Hurley, Ang Li et al. · 2022 · Molecular Therapy — Methods & Clinical Development
92. Contribution of Oxidative Stress (OS) in Calcific Aortic Valve Disease (CAVD): From Pathophysiology to Therapeutic Targets
    Daniela Maria Tănase, Emilia Valasciuc, Evelina Maria Gosav, Mariana Floria, Claudia Florida Costea, Nicoleta Dima, Ionuț Tudorancea, Minela Aida Maranducă, Ionela Lăcrămioara Șerban · 2022 · Cells
93. Association of Lipoprotein(a) Levels With Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis
    Omar Chehab, Ashkan Abdollahi, Seamus Paul Whelton, Colin O. Wu, Bharath Ambale‐Venkatesh, Wendy S. Post, David A. Bluemke, Michael Y. Tsai, João A.C. Lima · 2023 · Journal of the American College of Cardiology
94. Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease
    Raúl Fernández-Prado, María Vanessa Pérez-Gómez, Alberto Ortíz · 2020 · Clinical Kidney Journal
95. Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
    Henriette Thau, Sebastian Neuber, Maximilian Y. Emmert, Timo Z. Nazari‐Shafti · 2024 · Cardiology and Therapy
96. Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population
    Wann Jia Loh, Xuling Chang, Tar Choon Aw, Soon Kieng Phua, Adrian Fatt-Hoe Low, Mark Y. Chan, Gerald Francis Watts, Chew‐Kiat Heng · 2021 · Atherosclerosis
97. New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review
    Iveta Merćep, Dominik Strikić, Ana Marija Slišković, Željko Reiner · 2022 · Pharmaceuticals
98. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials
    Sining Xie, Federica Galimberti, Elena Olmastroni, Stefano Carugo, Alberico Luigi Catapano, Manuela Casula · 2025 · Atherosclerosis
99. Epigenetic Regulation of Vascular Smooth Muscle Cell Phenotype Switching in Atherosclerotic Artery Remodeling: A Mini-Review
    Michelle Zurek, Einari Aavik, Rahul Mallick, Seppo Ylä‐Herttuala · 2021 · Frontiers in Genetics
100. Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases
     Victoria Korneva, Tatjana Yurjevna Kuznetsova, Ulrich Julius · 2021 · Biomedicines